ProQR Therapeutics (NASDAQ:PRQR) Short Interest Update

ProQR Therapeutics (NASDAQ:PRQR – Get Rating) saw a large growth in short interest during the month of February. As of February 28th, there was short interest totalling 1,330,000 shares, a growth of 16.7% from the February 13th total of 1,140,000 shares. Based on an average daily trading volume, of 2,730,000 shares, the days-to-cover ratio is presently 0.5 days. Approximately 2.9% of the shares of the company are short sold.

Hedge Funds Weigh In On ProQR Therapeutics

Several institutional investors have recently made changes to their positions in PRQR. Prosight Management LP increased its holdings in shares of ProQR Therapeutics by 184.9% during the 2nd quarter. Prosight Management LP now owns 1,707,509 shares of the biopharmaceutical company’s stock valued at $1,328,000 after purchasing an additional 1,108,221 shares in the last quarter. M28 Capital Management LP increased its holdings in ProQR Therapeutics by 90.7% in the 4th quarter. M28 Capital Management LP now owns 1,910,600 shares of the biopharmaceutical company’s stock worth $7,069,000 after acquiring an additional 908,800 shares in the last quarter. Renaissance Technologies LLC purchased a new stake in ProQR Therapeutics in the 1st quarter worth $547,000. Marshall Wace LLP increased its holdings in ProQR Therapeutics by 472.8% in the 4th quarter. Marshall Wace LLP now owns 420,615 shares of the biopharmaceutical company’s stock worth $1,556,000 after acquiring an additional 347,185 shares in the last quarter. Finally, Opaleye Management Inc. increased its holdings in ProQR Therapeutics by 13.0% in the 2nd quarter. Opaleye Management Inc. now owns 2,740,000 shares of the biopharmaceutical company’s stock worth $2,131,000 after acquiring an additional 315,000 shares in the last quarter. 29.79% of the stock is owned by hedge funds and other institutional investors.

ProQR Therapeutics Price Performance

NASDAQ:PRQR opened at $3.16 on Wednesday. The company has a debt-to-equity ratio of 0.07, a current ratio of 3.86 and a quick ratio of 3.86. The firm has a market cap of $225.28 million, a price-to-earnings ratio of -2.93 and a beta of 0.12. The company has a 50 day moving average price of $3.04 and a 200-day moving average price of $1.87. ProQR Therapeutics has a 1-year low of $0.53 and a 1-year high of $3.78.

Wall Street Analyst Weigh In

A number of research firms have issued reports on PRQR. StockNews.com lowered shares of ProQR Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday. Raymond James raised their price target on shares of ProQR Therapeutics from $2.00 to $5.00 and gave the stock an “outperform” rating in a research report on Friday, December 23rd. Finally, Cantor Fitzgerald raised shares of ProQR Therapeutics from a “neutral” rating to an “overweight” rating and set a $5.00 price target for the company in a research report on Thursday, December 22nd. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $3.90.

ProQR Therapeutics Company Profile

(Get Rating)

ProQR Therapeutics NV is a clinical stage biopharmaceutical company. It is engaged in the discovery and development of RNA therapies for the treatment of severe genetic rare diseases with a focus on inherited retinal diseases, such as Leber congenital amaurosis 10, Usher syndrome type 2, and autosomal dominant retinitis pigmentosa.